Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 490346, 18 pages
http://dx.doi.org/10.1155/2013/490346
Review Article

Overview of Community-Acquired Pneumonia and the Role of Inflammatory Mechanisms in the Immunopathogenesis of Severe Pneumococcal Disease

1Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic Division of the National Health Laboratory Service, P.O. Box 2034, Pretoria 0001, South Africa
2Division of Pulmonology, Department of Internal Medicine, Charlotte Maxeke Johannesburg Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa

Received 2 September 2013; Revised 15 November 2013; Accepted 17 November 2013

Academic Editor: Jesús F. Bermejo-Martin

Copyright © 2013 Helen C. Steel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Feldman, A. J. Brink, G. A. Richards, G. Maartens, and E. D. Bateman, “Management of community-acquired pneumonia in adults,” South African Medical Journal, vol. 97, no. 12, pp. 1296–1306, 2007. View at Google Scholar · View at Scopus
  2. T. M. File Jr. and T. J. Marrie, “Burden of community-acquired pneumonia in North American adults,” Postgraduate Medicine, vol. 122, no. 2, pp. 130–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. R. E. Isturiz, C. M. Luna, and J. Ramirez, “Clinical and economic burden of pneumonia among adults in Latin America,” International Journal of Infectious Diseases, vol. 14, no. 10, pp. e852–e856, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-H. Song, V. Thamlikitkul, and P.-R. Hsueh, “Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region,” International Journal of Antimicrobial Agents, vol. 38, no. 2, pp. 108–117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Welte, “Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 31, no. 1, pp. 33–47, 2012. View at Google Scholar · View at Scopus
  6. T. Welte, A. Torres, and D. Nathwani, “Clinical and economic burden of community-acquired pneumonia among adults in Europe,” Thorax, vol. 67, no. 1, pp. 71–79, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Brown, “Community-acquired pneumonia,” Clinical Medicine, vol. 12, no. 6, pp. 538–543, 2012. View at Google Scholar
  8. A. S. Fauci and D. M. Morens, “The perpetual challenge of infectious diseases,” The New England Journal of Medicine, vol. 366, no. 5, pp. 454–461, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Blasi, M. Mantero, S. PierAchille, and P. Tarsia, “Understanding the burden of pneumococcal disease in adults,” Clinical Microbiology and Infections, vol. 18, supplement 5, pp. 7–14, 2012. View at Google Scholar
  10. C. Feldman and R. Anderson, “Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems,” Journal of Infection, vol. 67, no. 3, pp. 169–184, 2003. View at Google Scholar
  11. F. Sanz Herrero and J. Blanquer Olivas, “Microbiology and risk factors for community-acquired pneumonia,” Seminars in Respiratory and Critical Care Medicine, vol. 33, no. 3, pp. 220–231, 2012. View at Google Scholar
  12. G. Madeddu, M. Laura Fiori, and M. Stella Mura, “Bacterial community-acquired pneumonia in HIV-infected patients,” Current Opinion in Pulmonary Medicine, vol. 16, no. 3, pp. 201–207, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Feldman, K. P. Klugman, V. L. Yu et al., “Bacteraemic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome,” Journal of Infection, vol. 55, no. 2, pp. 125–135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Feldman and R. Anderson, “HIV-associated bacterial pneumonia,” Clinics in Chest Medicine, vol. 34, no. 2, pp. 205–216, 2013. View at Google Scholar
  15. I. Martin-Loeches, J. Solé-Violán, F. Rodríguez de Castro et al., “Variants at the promoter of the interleukin-6 gene are associated with severity and outcome of pneumococcal community-acquired pneumonia,” Intensive Care Medicine, vol. 38, no. 2, pp. 256–262, 2012. View at Google Scholar
  16. M. K. Dahmer, P. O'Cain, P. P. Patwari et al., “The influence of genetic variation in surfactant protein B on severe lung injury in African American children,” Critical Care Medicine, vol. 39, no. 5, pp. 1138–1144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. I. García-Laorden, F. Rodríguez de Castro, J. Solé-Violán et al., “Influence of genetic variability at the surfactant proteins A and D in community-acquired pneumonia: a prospective, observational, genetic study,” Critical Care, vol. 15, no. 1, article R57, 2011. View at Google Scholar
  18. A. Capelastegui, P. P. España, A. Bilbao et al., “Etiology of community-acquired pneumonia in a population-based study: link between etiology and patient characteristics, process-of-care, clinical evolution and outcomes,” BMC Infectious Diseases, vol. 12, article 134, 2012. View at Google Scholar
  19. C. Cillóniz, S. Ewig, R. Menéndez et al., “Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia,” Journal of Infection, vol. 65, no. 3, pp. 223–230, 2012. View at Google Scholar
  20. I. Martin-Loeches, A. Sanchez-Corral, E. Diaz et al., “Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A, (H1N1) virus,” Chest, vol. 139, no. 3, pp. 555–562, 2011. View at Google Scholar
  21. T. W. Rice, L. Rubinson, T. M. Uyeki et al., “Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States,” Critical Care Medicine, vol. 40, no. 5, pp. 1487–1498, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. R. J. Alanee, L. McGee, D. Jackson et al., “Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study,” Clinical Infectious Diseases, vol. 45, no. 1, pp. 46–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. D. M. Weinberger, Z. B. Harboe, E. A. M. Sanders et al., “Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis,” Clinical Infectious Diseases, vol. 51, no. 6, pp. 692–699, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Garcia-Vidal, C. Ardanuy, F. Tubau et al., “Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes,” Thorax, vol. 65, no. 1, pp. 77–81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Ahl, N. Littorin, A. Forsgren, I. Odenholt, F. Resman, and K. Riesbeck, “High incidence of septic shock caused by Streptococcus pneumoniae serotype 3: a retrospective epidemiological study,” BMC Infectious Diseases, vol. 13, article 492, 2013. View at Google Scholar
  26. T. Bewick, C. Sheppard, S. Greenwood et al., “Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia,” Thorax, vol. 67, no. 7, pp. 540–545, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Benfield, M. Skovgaard, H. C. Schønheyder et al., “Serotype distribution in non-bacteremic pneumococcal pneumonia: association with disease severity and implications for pneumococcal conjugate vaccines,” PLoS ONE, vol. 8, no. 8, pp. 1–7, 2013. View at Google Scholar
  28. J. Johnstone, S. R. Majumdar, J. D. Fox, and T. J. Marrie, “Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation,” Chest, vol. 134, no. 6, pp. 1141–1148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. E. G. Huijskens, A. J. van Erkel, F. M. Palmen, A. G. Buiting, J. A. Kluytmans, and J. W. Rossen, “Viral and bacterial aetiology of community-acquired pneumonia in adults,” Influenza and Other Respiratory Viruses, vol. 7, no. 4, pp. 567–573, 2013. View at Google Scholar
  30. L. A. Mandell, R. G. Wunderink, A. Anzueto et al., “Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults,” Clinical Infectious Diseases, vol. 44, supplement 2, pp. S27–S72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Martin-Loeches, T. Lisboa, A. Rodriguez et al., “Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia,” Intensive Care Medicine, vol. 36, no. 4, pp. 612–620, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Feldman and R. Anderson, “New insights into pneumococcal disease,” Respirology, vol. 14, no. 2, pp. 167–179, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. I. Restrepo, E. M. Mortensen, G. W. Waterer, R. G. Wunderink, J. J. Coalson, and A. Anzueto, “Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia,” European Respiratory Journal, vol. 33, no. 1, pp. 153–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Feldman and R. Anderson, “Bacteraemic pneumococcal pneumonia: current therapeutic options,” Drugs, vol. 71, no. 2, pp. 131–153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. H. C. Steel, A. J. Theron, R. Cockeran, R. Anderson, and C. Feldman, “Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics,” Mediators of Inflammation, vol. 2012, Article ID 584262, 17 pages, 2012. View at Publisher · View at Google Scholar
  36. V. F. Corrales-Medina and D. M. Musher, “Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review,” Journal of Infection, vol. 63, no. 3, pp. 187–199, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Asadi, W. I. Sligl, D. T. Eurich et al., “Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis,” Clinical Infectious Diseases, vol. 55, no. 3, pp. 371–380, 2012. View at Google Scholar
  38. D. F. Postma, C. H. van Werkhoven, S. M. Huijts, M. Bolkenbaas, J. J. Oosterheert, and M. J. M. Bonten, “New trends in the prevention and management of community-acquired pneumonia,” The Netherlands Journal of Medicine, vol. 70, no. 8, pp. 337–348, 2012. View at Google Scholar
  39. S. M. Doshi, P. A. Kulkarni, J. M. Liao, A. M. Rueda, and D. M. Musher, “The impact of statin and macrolide use on early survival in patients with pneumococcal pneumonia,” The American Journal of Medical Sciences, vol. 345, no. 3, pp. 173–177, 2013. View at Google Scholar
  40. “CAP-START study,” http://clinicaltrials.gov/ct2/show/NCT01660204.
  41. J. D. Fuller, A. McGeer, and D. E. Low, “Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 24, no. 12, pp. 780–788, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. R. N. Jones, M. R. Jacobs, and H. S. Sader, “Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia,” International Journal of Antimicrobial Agents, vol. 36, no. 3, pp. 197–204, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J. P. Lynch and G. G. Zhanel, “Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines,” Current Opinion in Pulmonary Medicine, vol. 16, no. 3, pp. 217–225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Feldman and R. Anderson, “Antibiotic resistance of pathogens causing community-acquired pneumonia,” Seminars in Respiratory and Critical Care Medicine, vol. 33, no. 3, pp. 232–243, 2012. View at Google Scholar
  45. V. L. Yu, C. C. C. Chiou, C. Feldman et al., “An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome,” Clinical Infectious Diseases, vol. 37, no. 2, pp. 230–237, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Feldman, “Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia,” Journal of Laboratory and Clinical Medicine, vol. 143, no. 5, pp. 269–283, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. P. L. Ho, T. L. Que, T. K. Ng, S. S. Chiu, R. W. Yung, and K. W. Tsang, “Clinical outcomes of bacteremic pneumococcal infections in an area with high resistance,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 25, no. 5, pp. 323–327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. L. R. Peterson, “Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?” Clinical Infectious Diseases, vol. 42, no. 2, pp. 224–233, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. I. M. Tleyjeh, H. M. Tlaygeh, R. Hejal, V. M. Montori, and L. M. Baddour, “The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis,” Clinical Infectious Diseases, vol. 42, no. 6, pp. 788–797, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. Clinical Laboratory Standards Institute Antimicrobial Susceptibility Testing, “M02-A10: Performance Standards for Antimicrobial Disk Susceptibility Tests,” 2008.
  51. A. M. Rivera and H. W. Boucher, “Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci,” Mayo Clinic Proceedings, vol. 86, no. 12, pp. 1230–1242, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. M. S. Niederman, “Recent advances in community-acquired pneumonia: inpatient and outpatient,” Chest, vol. 131, no. 4, pp. 1205–1215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Kolditz, S. Ewig, and G. Höffken, “Management-based risk prediction in community-acquired pneumonia by scores and biomarkers,” European Respiratory Journal, vol. 41, no. 4, pp. 974–984, 2013. View at Google Scholar
  54. C. Feldman, “Prognostic scoring systems: which one is best?” Current Opinion in Infectious Diseases, vol. 20, no. 2, pp. 165–169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. J. M. Pereira, J. A. Paiva, and J. Rello, “Assessing severity of patients with community-acquired pneumonia,” Seminars in Respiratory and Critical Care Medicine, vol. 33, no. 3, pp. 272–283, 2012. View at Google Scholar
  56. C. Marti, N. Garin, O. Grosgurin et al., “Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis,” Critical Care, vol. 16, no. 4, article R141, 2012. View at Google Scholar
  57. G. Lippi, T. Meschi, and G. Cervellin, “Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneumonia: clinical evidence and perspectives,” European Journal of Internal Medicine, vol. 22, no. 5, pp. 460–465, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Berg and B. Ø. Lindhardt, “The role of procalcitonin in adult patients with community-acquired pneumonia: a systemativ review,” Danish Medical Bulletin, vol. 59, no. 3, Article ID A4357, 2012. View at Google Scholar · View at Scopus
  59. P. Schuetz, M. Briel, M. Christ-Crain et al., “Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis,” Clinical Infectious Diseases, vol. 55, no. 5, pp. 651–662, 2012. View at Google Scholar
  60. P. Schuetz, B. Müller, M. Christ-Crain et al., “Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections,” Cochrane Database of Systematic Reviews, vol. 9, Article ID CD007498, 2012. View at Publisher · View at Google Scholar
  61. S. Aliberti and F. Blasi, “Clinical stability versus clinical failure in patients with community-acquired pneumonia,” Seminars in Respiratory and Critical Care Medicine, vol. 33, no. 3, pp. 284–291, 2012. View at Google Scholar
  62. J. Bordón, P. Peyrani, G. N. Brock et al., “The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study,” Chest, vol. 133, no. 3, pp. 618–624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. V. Kaplan, G. Clermont, M. F. Griffin et al., “Pneumonia: still the old man's friend?” Archives of Internal Medicine, vol. 163, no. 3, pp. 317–323, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. E. M. Mortensen and M. L. Metersky, “Long-term mortality after pneumonia,” Seminars in Respiratory and Critical Care Medicine, vol. 33, no. 3, pp. 319–324, 2012. View at Google Scholar
  65. J. Johnstone, D. T. Eurich, S. R. Majumdar, Y. Jin, and T. J. Marrie, “Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study,” Medicine, vol. 87, no. 6, pp. 329–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. V. F. Corrales-Medina, D. M. Musher, S. Shachkina, and J. A. Chirinos, “Acute pneumonia and the cardiovascular system,” The Lancet, vol. 381, no. 9865, pp. 496–505, 2013. View at Google Scholar
  67. G. E. Carr, T. C. Yeun, J. F. McConville et al., “Early cardiac arrest in patients hospitalized with pneumonia: a report from the American Heart Association’s Get With the Guidelines-Resuscitation Program,” Chest, vol. 141, no. 6, pp. 1528–1536, 2012. View at Google Scholar
  68. V. F. Corrales-Medina, D. M. Musher, G. A. Wells, J. A. Chirinos, L. Chen, and M. J. Fine, “Cardiac complications in patients with community-acquired pneumonia incidence, timing, risk factors, and association with short-term mortality,” Circulation, vol. 125, no. 6, pp. 773–781, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. N. Soto-Gomez, A. Anzueto, G. W. Waterer, M. I. Restrepo, and E. M. Mortensen, “Pneumonia: an arrhythmogenic disease?” The American Journal of Medicine, vol. 126, no. 1, pp. 43–48, 2013. View at Google Scholar
  70. A. Kadioglu, J. N. Weiser, J. C. Paton, and P. W. Andrew, “The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease,” Nature Reviews Microbiology, vol. 6, no. 4, pp. 288–301, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Jonsson, D. M. Musher, and A. Chapman, “Phagocytosis and killing of common bacterial pathogens of the lung by human alveolar macrophages,” Journal of Infectious Diseases, vol. 152, no. 1, pp. 4–13, 1985. View at Google Scholar · View at Scopus
  72. D. M. Weinberger, K. Trzciński, Y. J. Lu et al., “Pneumococcal capsular polysaccharide structure predicts serotype prevalence,” PLoS Pathogens, vol. 5, no. 6, Article ID e1000476, 2009. View at Google Scholar
  73. M. A. Barocchi, J. Ries, X. Zogaj et al., “A pneumococcal pilus influences virulence and host inflammatory responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 8, pp. 2857–2862, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. F. Bagnoli, M. Moschioni, C. Donati et al., “A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells,” Journal of Bacteriology, vol. 190, no. 15, pp. 5480–5492, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Hilleringmann, F. Giusti, B. C. Baudner et al., “Pneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg A,” PLoS Pathogens, vol. 4, no. 3, Article ID e1000026, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Orrskog, S. Rounioja, T. Spadafina et al., “Pilus adhesion RrgA interacts with complement receptor 3, thereby affecting macrophage function and systemic pneumococcal disease,” MBio, vol. 4, no. 1, Article ID :e00535-12, 2012. View at Publisher · View at Google Scholar
  77. A. Basset, F. Zhang, C. Benes et al., “Toll-like receptor (TLR) 2 mediates inflammatory responses to oligomerized RrgA pneumococcal pilus type 1 protein,” Journal of Biological Chemistry, vol. 288, no. 4, pp. 2665–2675, 2013. View at Google Scholar
  78. M. Domenech, E. Ramos-Sevillano, E. Garcia, M. Moscoso, and J. Yuste, “Biofilm formation avoids complement immunity and phagocytosis of Streptococcus pneumoniae,” Infection and Immunity, vol. 81, no. 7, pp. 2606–2615, 2013. View at Google Scholar
  79. C. Feldman, R. Anderson, R. Cockeran, T. Mitchell, P. Cole, and R. Wilson, “The effects of pneumolysin and hydrogen peroxide, alone and in combination, on human ciliated epithelium in vitro,” Respiratory Medicine, vol. 96, no. 8, pp. 580–585, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. G. Regev-Yochay, K. Trzcinski, C. M. Thompson, M. Lipsitch, and R. Malley, “SpxB is a suicide gene of Streptococcus pneumoniae and confers a selective advantage in an in vivo competitive colonization model,” Journal of Bacteriology, vol. 189, no. 18, pp. 6532–6539, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. C. D. Pericone, K. Overweg, P. W. M. Hermans, and J. N. Weiser, “Inhibitory and bactericidal effects of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper respiratory tract,” Infection and Immunity, vol. 68, no. 7, pp. 3990–3997, 2000. View at Publisher · View at Google Scholar · View at Scopus
  82. J. B. Rubins and E. N. Janoff, “Pneumolysin: a multifunctional pneumococcal virulence factor,” Journal of Laboratory and Clinical Medicine, vol. 131, no. 1, pp. 21–27, 1998. View at Google Scholar · View at Scopus
  83. M. J. Jedrzejas, “Pneumococcal virulence factors: structure and function,” Microbiology and Molecular Biology Reviews, vol. 65, no. 2, pp. 187–207, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. A. M. Mitchell and T. J. Mitchell, “Streptococcus pneumoniae: virulence factors and variation,” Clinical Microbiology and Infection, vol. 16, no. 5, pp. 411–418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. H. M. Marriott, T. J. Mitchell, and D. H. Dockrell, “Pneumolysin: a double-edged sword during the host-pathogen interaction,” Current Molecular Medicine, vol. 8, no. 6, pp. 497–509, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. A. M. Berry, R. A. Lock, D. Hansman, and J. C. Paton, “Contribution of autolysin to virulence of Streptococcus pneumoniae,” Infection and Immunity, vol. 57, no. 8, pp. 2324–2330, 1989. View at Google Scholar · View at Scopus
  87. P. Mellroth, R. Daniels, A. Eberhardt et al., “LytA, major autolysin of Streptococcus pneumoniae, requires access to nascent peptidoglycan,” Journal of Biological Chemistry, vol. 287, no. 14, pp. 11018–11029, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. K. K. Gosink, E. R. Mann, C. Guglielmo, E. I. Tuomanen, and H. R. Masure, “Role of novel choline binding proteins in virulence of Streptococcus pneumoniae,” Infection and Immunity, vol. 68, no. 10, pp. 5690–5695, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. C. J. Orihuela, J. Mahdavi, J. Thornton et al., “Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models,” Journal of Clinical Investigation, vol. 119, no. 6, pp. 1638–1646, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Attali, C. Frolet, C. Durmort, J. Offant, T. Vernet, and A. M. Di Guilmi, “Streptococcus pneumoniae choline-binding protein E interaction with plasminogen/plasmin stimulates migration across the extracellular matrix,” Infection and Immunity, vol. 76, no. 2, pp. 466–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. B. Ren, A. J. Szalai, O. Thomas, S. K. Hollingshead, and D. E. Briles, “Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae,” Infection and Immunity, vol. 71, no. 1, pp. 75–85, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. M. J. Jedrzejas, “Unveiling molecular mechanisms of pneumococcal surface protein A interactions with antibodies and lactoferrin,” Clinica Chimica Acta, vol. 367, no. 1-2, pp. 1–10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Voss, T. Hallström, M. Saleh et al., “The choline-binding protein PspC of Streptococcus pneumoniae interacts with the C-terminal heparin-binding domain of vitronectin,” Journal of Biological Chemistry, vol. 288, no. 22, pp. 15614–15627, 2013. View at Google Scholar
  94. A. R. Holmes, R. McNab, K. W. Millsap et al., “The pavA gene of Streptococcus pneumoniae encodes a fibronectin-binding protein that is essential for virulence,” Molecular Microbiology, vol. 41, no. 6, pp. 1395–1408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Pracht, C. Elm, J. Gerber et al., “PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation,” Infection and Immunity, vol. 73, no. 5, pp. 2680–2689, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. I. Jensch, G. Gámez, M. Rothe et al., “PavB is a surface-exposed adhesin of Streptococcus pneumoniae contributing to nasopharyngeal colonization and airways infections,” Molecular Microbiology, vol. 77, no. 1, pp. 22–43, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. J. M. Anderton, G. Rajam, S. Romero-Steiner et al., “E-cadherin is a receptor for the common protein pneumococcal surface adhesin A (PsaA) of Streptococcus pneumoniae,” Microbial Pathogenesis, vol. 42, no. 5-6, pp. 225–236, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. G. Rajam, D. J. Phillips, E. White et al., “A functional epitope of the pneumococcal surface adhesin A activates nasopharyngeal cells and increases bacterial internalization,” Microbial Pathogenesis, vol. 44, no. 3, pp. 186–196, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Yamaguchi, Y. Terao, Y. Mori, S. Hamada, and S. Kawabata, “PfbA, a novel plasmin- and fibronectin-binding protein of Streptococcus pneumoniae, contributes to fibronectin-dependent adhesion and antiphagocytosis,” Journal of Biological Chemistry, vol. 283, no. 52, pp. 36272–36279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. D. H. Dockrell, M. K. B. White, and T. J. Mitchell, “Pneumococcal pneumonia: mechanisms of infection and resolution,” Chest, vol. 142, no. 2, pp. 482–497, 2012. View at Google Scholar
  101. C. J. Sanchez, N. Kumar, A. Lizcano et al., “Streptococcus pneumoniae in biofilms are unable to cause invasive disease due to altered virulence determinant production,” PLoS ONE, vol. 6, no. 12, Article ID e28738, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Zhang, A. W. Masi, V. Barniak, K. Mountzouros, M. K. Hostetter, and B. A. Green, “Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge,” Infection and Immunity, vol. 69, no. 6, pp. 3827–3836, 2001. View at Publisher · View at Google Scholar · View at Scopus
  103. C. Trappetti, A. Kadioglu, M. Carter et al., “Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host,” Journal of Infectious Diseases, vol. 199, no. 10, pp. 1497–1505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. G. Xu, J. A. Potter, R. J. M. Russell, M. R. Oggioni, P. W. Andrew, and G. L. Taylor, “Crystal structure of the NanB sialidase from Streptococcus pneumoniae,” Journal of Molecular Biology, vol. 384, no. 2, pp. 436–449, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. J. L. Britton, T. J. Buckeridge, A. Finn, A. Kadioglu, and H. F. Jenkinson, “Pneumococcal neuraminidase A: an essential upper airway colonization factor for Streptococcus pneumoniae,” Molecular Oral Microbiology, vol. 27, no. 4, pp. 270–283, 2012. View at Google Scholar
  106. D. Parker, G. Soong, P. Planet, J. Brower, A. J. Ratner, and A. Prince, “The NanA neuraminidase of Streptococcus pneumoniae is involved in biofilm formation,” Infection and Immunity, vol. 77, no. 9, pp. 3722–3730, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. K. Beiter, F. Wartha, B. Albiger, S. Normark, A. Zychlinsky, and B. Henriques-Normark, “An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps,” Current Biology, vol. 16, no. 4, pp. 401–407, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. A. F. Moon, M. Midon, G. Meiss, A. Pingoud, R. E. London, and L. C. Pedersen, “Structural insights into catalytic and substrate binding mechanisms of the strategic EndA nuclease from Streptococcus pneumoniae,” Nucleic Acids Research, vol. 39, no. 7, pp. 2943–2953, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. C. E. Blue, G. K. Paterson, A. R. Kerr, M. Bergé, J. P. Claverys, and T. J. Mitchell, “ZmpB, a novel virulence factor of Streptococcus pneumoniae that induces tumor necrosis factor alpha production in the respiratory tract,” Infection and Immunity, vol. 71, no. 9, pp. 4925–4935, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Bergé, P. García, F. Iannelli et al., “The puzzle of zmpB and extensive chain formation, autolysis defect and non-translocation of choline-binding proteins in Streptococcus pneumoniae,” Molecular Microbiology, vol. 39, no. 6, pp. 1651–1660, 2001. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Niu, M. Luo, J. Tang et al., “Structural basis of the novel S. pneumoniae virulence factor, GHIP, a glycosyl hydrolase 25 participating in host-cell invasion,” PLoS ONE, vol. 8, no. 7, Article ID e68647, 2013. View at Google Scholar
  112. J. O. Lee, J. Y. Kim, D. K. Rhee, and S. Pyo, “Streptococcus pneumoniae ClpP protease induces apoptosis via caspase-dependent pathway in human neuroblastoma cells: cytoplasmic relocalization of p53,” Toxicon, vol. 70, pp. 142–152, 2013. View at Google Scholar
  113. K. Beilharz, L. Nováková, D. Fadda, P. Branny, O. Massidda, and J.-W. Veening, “Control of cell division in Streptococcus pneumoniae by the conserved Ser/Thr protein kinase StkP,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 15, pp. E905–E913, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. U. Koppe, N. Suttorp, and B. Opitz, “Recognition of Streptococcus pneumoniae by the innate immune system,” Cellular Microbiology, vol. 14, no. 4, pp. 460–466, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. N. Saïd-Sadier and D. M. Ojcius, “Alarmins, inflammasomes and immunity,” Biomedical Journal, vol. 35, no. 6, pp. 437–449, 2012. View at Google Scholar
  116. R. Malley, “Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development,” Journal of Molecular Medicine, vol. 88, no. 2, pp. 135–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Olliver, J. Hiew, P. Mellroth, B. Henriques-Normark, and P. Bergman, “Human monocytes promote Th1 and Th17 responses to Streptococcus pneumoniae,” Infection and Immunity, vol. 79, no. 10, pp. 4210–4217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. J. N. Weiser, R. Austrian, P. K. Sreenivasan, and H. R. Masure, “Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization,” Infection and Immunity, vol. 62, no. 6, pp. 2582–2589, 1994. View at Google Scholar · View at Scopus
  119. B. Henriques-Normark and E. I. Tuomanen, “The pneumococcus: epidemiology, microbiology, and pathogenesis,” Cold Spring Harbour Perspectives in Medicine, vol. 3, no. 7, Article ID a010215, 2013. View at Google Scholar
  120. C. Hyams, S. Opel, W. Hanage et al., “Effects of Streptococcus pneumoniae strain background on complement resistance,” PLoS ONE, vol. 6, no. 10, Article ID e24581, 2011. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Hyams, K. Trzcinski, E. Camberlein et al., “Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonisation with C3b/iC3b,” Infection and Immunity, vol. 81, no. 1, pp. 354–363, 2013. View at Google Scholar
  122. A. D. Ogunniyi, P. Giammarinaro, and J. C. Paton, “The genes encoding virulence-associated proteins and the capsule of Streptococcus pneumoniae are upregulated and differentially expressed in vivo,” Microbiology, vol. 148, no. 7, pp. 2045–2053, 2002. View at Google Scholar · View at Scopus
  123. S. Hammerschmidt, S. Wolff, A. Hocke, S. Rosseau, E. Müller, and M. Rohde, “Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells,” Infection and Immunity, vol. 73, no. 8, pp. 4653–4667, 2005. View at Publisher · View at Google Scholar · View at Scopus
  124. J. L. Rodriguez, A. B. Dalia, and J. N. Weiser, “Increased chain length promotes pneumococcal adherence and colonization,” Infection and Immunity, vol. 80, no. 10, pp. 3454–3459, 2012. View at Google Scholar
  125. A. Lizcano, T. Chin, K. Sauer, E. I. Tuomanen, and C. J. Orihuela, “Early biofilm formation on microtiter plates is not correlated with the invasive disease potential of Streptococcus pneumoniae,” Microbial Pathogenesis, vol. 48, no. 3-4, pp. 124–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. L. Qin, Y. Kida, Y. Imamura, K. Kuwano, and H. Watanabe, “Impaired capsular polysaccharide is relevant to enhanced biofilm formation and lower virulence in Streptococcus pneumoniae,” Journal of Infection and Chemotherapy, vol. 19, no. 2, pp. 261–271, 2013. View at Google Scholar
  127. N. D. Mutepe, R. Cockeran, H. C. Steel et al., “Effects of cigarette smoke condensate on pneumococcal biofilm formation and pneumolysin,” European Respiratory Journal, vol. 41, no. 2, pp. 392–395, 2013. View at Google Scholar
  128. H. Yesilkaya, V. F. Andisi, P. W. Andrew, and J. J. Bijlsma, “Streptococcus pneumoniae and reactive oxygen species: an unusual approach to living with radicals,” Trends in Immunology, vol. 21, no. 4, pp. 187–195, 2013. View at Google Scholar
  129. S. M. Carvalho, V. Farshchi Andisi, H. Gradstedt et al., “Pyruvate oxidase influences the sugar utilization pattern and capsule production in Streptococcus pneumoniae,” PLoS ONE, vol. 8, no. 7, Article ID e68277, 2013. View at Google Scholar
  130. R. López and E. García, “Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage,” FEMS Microbiology Reviews, vol. 28, no. 5, pp. 553–580, 2004. View at Publisher · View at Google Scholar · View at Scopus
  131. G. Xu, M. J. Kiefel, J. C. Wilson, P. W. Andrew, M. R. Oggioni, and G. L. Taylor, “Three Streptococcus pneumoniae sialidases: three different products,” Journal of the American Chemical Society, vol. 133, no. 6, pp. 1718–1721, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. H. C. Krivan, D. D. Roberts, and V. Ginsburg, “Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAcβ1-4Gal found in some glycolipids,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 16, pp. 6157–6161, 1988. View at Google Scholar · View at Scopus
  133. L. Gualdi, J. K. Hayre, A. Gerlini et al., “Regulation of neuraminidase expression in Streptococcus pneumoniae,” BMC Microbiology, vol. 12, article 200, 2012. View at Publisher · View at Google Scholar
  134. C. Feldman, R. Cockeran, M. J. Jedrzejas, T. J. Mitchell, and R. Anderson, “Hyaluronidase augments pneumolysin-mediated injury to human ciliated epithelium,” International Journal of Infectious Diseases, vol. 11, no. 1, pp. 11–15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. M. Littmann, B. Albiger, A. Frentzen, S. Normark, B. Henriques-Normark, and L. Plant, “Streptococcus pneumoniae evades human dendritic cell surveillance by pneumolysin expression,” EMBO Molecular Medicine, vol. 1, no. 4, pp. 211–222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. M. Witzenrath, B. Gutbier, A. C. Hocke et al., “Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia,” Critical Care Medicine, vol. 34, no. 7, pp. 1947–1954, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. E. A. McNeela, Á. Burke, D. R. Neill et al., “Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4,” PLoS Pathogens, vol. 6, no. 11, Article ID e1001191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. R. Cockeran, A. J. Theron, H. C. Steel et al., “Proinflammatory interactions of pneumolysin with human neutrophils,” Journal of Infectious Diseases, vol. 183, no. 4, pp. 604–611, 2001. View at Publisher · View at Google Scholar · View at Scopus
  139. R. Cockeran, H. C. Steel, T. J. Mitchell, C. Feldman, and R. Anderson, “Pneumolysin potentiates production of prostaglandin E2 and leukotriene B4 by human neutrophils,” Infection and Immunity, vol. 69, no. 5, pp. 3494–3496, 2001. View at Publisher · View at Google Scholar · View at Scopus
  140. H. Fickl, R. Cockeran, H. C. Steel et al., “Pneumolysin-mediated activation of NFκB in human neutrophils is antagonized by docosahexaenoic acid,” Clinical and Experimental Immunology, vol. 140, no. 2, pp. 274–281, 2005. View at Publisher · View at Google Scholar · View at Scopus
  141. A. J. Ratner, K. R. Hippe, J. L. Aguilar, M. H. Bender, A. L. Nelson, and J. N. Weiser, “Epithelial cells are sensitive detectors of bacterial pore-forming toxins,” Journal of Biological Chemistry, vol. 281, no. 18, pp. 12994–12998, 2006. View at Publisher · View at Google Scholar · View at Scopus
  142. T. Koga, H. L. Jae, H. Jono et al., “Tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signaling,” Journal of Biological Chemistry, vol. 283, no. 18, pp. 12546–12554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. J. L. Aguilar, R. Kulkarni, T. M. Randis et al., “Phosphatase-dependent regulation of epithelial mitogen-activated protein kinase responses to toxin-induced membrane pores,” PLoS ONE, vol. 4, no. 11, Article ID e8076, 2009. View at Google Scholar · View at Scopus
  144. R. Cockeran, C. Durandt, C. Feldman, T. J. Mitchell, and R. Anderson, “Pneumolysin activates the synthesis and release of interleukin-8 by human neutrophils in vitro,” Journal of Infectious Diseases, vol. 186, no. 4, pp. 562–565, 2002. View at Publisher · View at Google Scholar · View at Scopus
  145. R. Malley, P. Henneke, S. C. Morse et al., “Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 4, pp. 1966–1971, 2003. View at Publisher · View at Google Scholar · View at Scopus
  146. G. N. Barber, “Cytoplasmic DNA innate immune pathways,” Immunological Reviews, vol. 243, no. 1, pp. 99–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. S. Sharma and K. A. Fitzgerald, “Innate immune sensing of DNA,” PLoS Pathogens, vol. 7, no. 4, Article ID e1001310, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. S. Hahn, S. Giaglis, C. S. Chowdury, I. Hösli, and P. Hasler, “Modulation of neutrophil NETosis: interplay between infectious agents and underlying host physiology,” Seminars in Immunopathology, vol. 35, no. 4, pp. 439–453, 2013. View at Google Scholar
  149. Y. Mori, M. Yamaguchi, Y. Terao, S. Hamada, T. Ooshima, and S. Kawabata, “α-enolase of Streptococcus pneumoniae induces formation of neutrophil extracellular traps,” Journal of Biological Chemistry, vol. 287, no. 13, pp. 10472–10481, 2012. View at Publisher · View at Google Scholar · View at Scopus
  150. A. N. Moorthy, T. Narasaraju, P. Rai et al., “In Vivo and in vitro studies on the roles of neutrophil extracellular traps during secondary pneumococcal pneumonia after primary pulmonary influenza infection,” Frontiers in Immunology, vol. 4, no. 56, pp. 1–13, 2013. View at Google Scholar
  151. M. Saffarzadeh, C. Juenemann, M. A. Queisser et al., “Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones,” PLoS ONE, vol. 7, no. 2, Article ID e32366, 2012. View at Publisher · View at Google Scholar · View at Scopus
  152. D. R. Gough and T. G. Cotter, “Hydrogen peroxide: a Jekyll and Hyde signalling molecule,” Cell Death and Disease, vol. 2, no. 10, article e213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  153. E. Veal and A. Day, “Hydrogen peroxide as a signaling molecule,” Antioxidants and Redox Signaling, vol. 15, no. 1, pp. 147–151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  154. R. Anderson, H. C. Steel, R. Cockeran et al., “Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 5, pp. 1155–1158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. B. M. Vanaudenaerde, W. A. Wuyts, N. Geudens et al., “Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells,” The American Journal of Transplantation, vol. 7, no. 1, pp. 76–82, 2007. View at Publisher · View at Google Scholar · View at Scopus
  156. T. Kikuchi, K. Hagiwara, Y. Honda et al., “Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-ΚB transcription factors,” Journal of Antimicrobial Chemotherapy, vol. 49, no. 5, pp. 745–755, 2002. View at Google Scholar · View at Scopus
  157. I. Suzaki, K. Asano, A. Kanei, and H. Suzaki, “Enhancement of thioredoxin production from nasal epithelial cells by the macrolide antibiotic, clarithromycin in vitro,” In Vivo, vol. 27, no. 3, pp. 351–356, 2013. View at Google Scholar
  158. M. Li, X. Zhong, Z. He et al., “Effect of erythromycin on cigarette-induced histone deacetylase protein expression and nuclear factor-κB activity in human macrophages in vitro,” International Immunopharmacology, vol. 12, no. 4, pp. 643–650, 2012. View at Publisher · View at Google Scholar · View at Scopus
  159. E. J. Giamarellos-Bourboulis, J.-C. Pechère, C. Routsi et al., “Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia,” Clinical Infectious Diseases, vol. 46, no. 8, pp. 1157–1164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  160. A. J. Walkey and R. S. Wiener, “Macrolide antibiotics and survival in patients with acute lung injury,” Chest, vol. 141, no. 5, pp. 1153–1159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  161. Å. Karlström, K. L. Boyd, B. K. English, and J. A. McCullers, “Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza,” Journal of Infectious Diseases, vol. 199, no. 3, pp. 311–319, 2009. View at Publisher · View at Google Scholar · View at Scopus
  162. R. G. Wunderink, “Adjunctive therapy in community-acquired pneumonia,” Seminars in Respiratory and Critical Care Medicine, vol. 30, no. 2, pp. 146–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. M. J. Noto and A. P. Wheeler, “Macrolides for acute lung injury,” Chest, vol. 141, no. 5, pp. 1131–1132, 2012. View at Publisher · View at Google Scholar · View at Scopus
  164. P. J. Barnes, “New molecular targets for the treatment of neutrophilic diseases,” Journal of Allergy and Clinical Immunology, vol. 119, no. 5, pp. 1055–1062, 2007. View at Publisher · View at Google Scholar · View at Scopus
  165. M. C. Brouwer, S. G. B. Heckenberg, J. de Gans, L. Spanjaard, J. B. Reitsma, and D. van de Beek, “Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis,” Neurology, vol. 75, no. 17, pp. 1533–1539, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. M. Confalonieri, R. Urbino, A. Potena et al., “Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study,” The American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 3, pp. 242–248, 2005. View at Publisher · View at Google Scholar · View at Scopus
  167. C. Garcia-Vidal, E. Calbo, V. Pascual, C. Ferrer, S. Quintana, and J. Garau, “Effects of systemic steroids in patients with severe community-acquired pneumonia,” European Respiratory Journal, vol. 30, no. 5, pp. 951–956, 2007. View at Publisher · View at Google Scholar · View at Scopus
  168. K. Mikami, M. Suzuki, H. Kitagawa et al., “Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization,” Lung, vol. 185, no. 5, pp. 249–255, 2007. View at Publisher · View at Google Scholar · View at Scopus
  169. D. Snijders, J. M. A. Daniels, C. S. de Graaff, T. S. van der Werf, and W. G. Boersma, “Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial,” The American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 9, pp. 975–982, 2010. View at Publisher · View at Google Scholar · View at Scopus
  170. E. Polverino, C. Cillóniz, P. Dambrava et al., “Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome,” Respirology, vol. 18, no. 2, pp. 263–271, 2013. View at Google Scholar
  171. S. C. A. Meijvis, H. Hardeman, H. H. F. Remmelts et al., “Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 377, no. 9782, pp. 2023–2030, 2011. View at Publisher · View at Google Scholar · View at Scopus
  172. H. H. Remmelts, S. C. A. Meijvis, D. H. Biesma et al., “Dexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia,” Clinical and Vaccine Immunology, vol. 19, no. 9, pp. 1532–1538, 2012. View at Google Scholar
  173. W. Nie, Y. Zhang, J. Cheng, and Q. Xiu, “Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis,” PLoS ONE, vol. 7, no. 10, Article ID e47926, 2012. View at Google Scholar
  174. “Extended Steroid in CAP(e) (ESCAPe),” http://clinicaltrials.gov/show/NCT01283009.
  175. E. Mira and S. Mañes, “Immunomodulatory and anti-inflammatory activities of statins,” Endocrine, Metabolic and Immune Disorders, vol. 9, no. 3, pp. 237–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  176. M. Massaro, A. Zampolli, E. Scoditti et al., “Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability,” Cardiovascular Research, vol. 86, no. 2, pp. 311–320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  177. Y. Wang, M. X. Zhang, X. Meng et al., “Atorvastatin suppresses LPS-induced rapid upregulation of toll-like receptor 4 and its signaling pathway in endothelial cells,” The American Journal of Physiology, vol. 300, no. 5, pp. H1743–H1752, 2011. View at Publisher · View at Google Scholar · View at Scopus
  178. P.-O. Leung, S.-H. Wang, S.-H. Lu, W.-H. Chou, C.-Y. Shiau, and T.-C. Chou, “Simvastatin inhibits pro-inflammatory mediators through induction of heme oxygenase-1 expression in lipopolysaccharide-stimulated RAW264.7 macrophages,” Toxicology Letters, vol. 207, no. 2, pp. 159–166, 2011. View at Publisher · View at Google Scholar · View at Scopus
  179. M. F. Mrad, C. A. Mouawad, M. Al-Hariri, A. A. Eid, J. Alam, and A. Habib, “Statins modulate transcriptional activity of heme-oxygenase-1 promoter in NIH 3T3 cells,” Journal of Cellular Biochemistry, vol. 113, no. 11, pp. 3466–3475, 2012. View at Google Scholar
  180. C. H. Serezani, M. N. Ballinger, D. M. Aronoff, and M. Peters-Golden, “Cyclic AMP: master regulator of innate immune cell function,” The American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 2, pp. 127–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  181. M. A. Matthay, R. G. Brower, S. Carson et al., “Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury,” The American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 5, pp. 561–568, 2011. View at Publisher · View at Google Scholar · View at Scopus
  182. F. G. Smith, G. D. Perkins, S. Gates et al., “Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial,” The Lancet, vol. 379, no. 9812, pp. 229–235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  183. C. M. Gravett, A. J. Theron, H. C. Steel et al., “Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils,” European Respiratory Journal, vol. 36, no. 6, pp. 1417–1424, 2010. View at Publisher · View at Google Scholar · View at Scopus
  184. M. J. Stables, J. Newson, S. S. Ayoub, J. Brown, C. J. Hyams, and D. W. Gilroy, “Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria,” Blood, vol. 116, no. 16, pp. 2950–2959, 2010. View at Publisher · View at Google Scholar · View at Scopus